B-chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of long-lived B lymphocytes that express high levels of Bcl-2. We examined the involvement of CED-3/ICE-like proteases in the apoptosis of B-CLL cells. One of the substrates of these proteases is poly(ADP [adenosine 5′-diphosphate]-ribose) polymerase (PARP). The effect of different factors that induce the apoptosis of B-CLL cells on the proteolytic cleavage of PARP has been studied. Treatment of B-CLL cells with different concentrations of dexamethasone (1 to 1,000 μmol/L) induced in a dose-dependent manner the cleavage of PARP. Dexamethasone induced PARP cleavage after 12 hours of incubation, which was almost complete at 48 hours. PARP cleavage during apoptosis of B-CLL cells was studied in cells from eight patients and a correlation was found between cell viability and the degree of PARP cleavage. Incubation in vitro of B-CLL cells with fludarabine for 48 hours induced PARP cleavage in all the cases studied. Protein kinase C (PKC) activation with 100 nmol/L TPA (12-O-tetradecanoylphorbol 13-acetate) or incubation with interleukin-4 (10 ng/mL) prevented either dexamethasone- or fludarabine-induced proteolysis of PARP. Incubation of B-CLL cells with the CED-3/ICE–like protease inhibitor Z-VAD.fmk inhibited spontaneous and dexamethasone-induced PARP cleavage and DNA fragmentation in a dose-dependent manner. Furthermore, Z-VAD.fmk prevented the cytotoxic effect of dexamethasone. These results indicate that CED-3/ICE–like proteases play an important role in the apoptosis of B-CLL cells.

B-CHRONIC LYMPHOCYTIC leukemia (B-CLL) is characterized by the accumulation of monoclonal CD5+ B lymphocytes.1 The majority of circulating cells appear to be nondividing and it has been suggested that the clonal excess of B cells results from decreased cell death rather than increased proliferation.2 

Apoptosis is the physiological process whereby most cells, including B lymphocytes, are eliminated, which leads to homeostasis.3 Apoptosis is characterized by morphological and biochemical changes that include cell shrinkage, membrane blebbing, chromatin condensation, and endogenous endonuclease activation.4 Apoptosis of B-CLL lymphocytes can be regulated by different cytokines.5 When B-CLL cells are placed in culture medium, they undergo apoptosis.6 This spontaneous apoptosis in cultured B-CLL cells is probably triggered by the absence of survival factors present in vivo. Candidate survival factors that prevent apoptosis of B-CLL cells in vitro are: interleukin-4 (IL-4), interferon-γ (IFN-γ), IFN-α, IL-2, IL-6, IL-8, and IL-13.7-14 On the other hand, IL-10 and IL-5 induce apoptosis in these cells.15,16 Glucocorticoids and other chemotherapeutic agents used clinically, like chlorambucil, 2-chloro-2′-deoxyadenosine and fludarabine, induce apoptosis in CLL lymphocytes,17-21 suggesting that apoptosis is one of the mechanisms of their therapeutic action.

The proto-oncogene product Bcl-2 has been shown to inhibit cell death induced by a variety of apoptotic stimuli and in numerous cell types.22 The Bcl-2 protein is overexpressed in B-CLL lymphocytes,23-25 which may inhibit the apoptosis of these cells. The mechanism of action of Bcl-2 is still unknown.26,27 It has been proposed that Bcl-2 has either an antioxidant activity28,29 or the capacity to interfere with intracellular calcium signaling.30 Protein kinase C (PKC) activation23 and also incubation with different cytokines, including IL-4,7 IL-8,13 and IFN-α,10 increase Bcl-2 levels in B-CLL cells and consequently block apoptosis. These findings suggest that a common step, inhibitable by Bcl-2, is activated during B-CLL apoptosis.

It is becoming evident that cysteine-proteases of the CED-3/ICE family play an important role in apoptosis.31-33 Inhibition of these proteases can block apoptosis triggered by different stimuli. They are synthesized as proenzymes, which are proteolytically processed to form active heterodimeric enzymes, but the mechanisms of control are largely unknown. Several substrates of these proteases have been described.32 Some of these proteases can cleave and inactivate poly(ADP-ribose) polymerase (PARP), an enzyme that participates in DNA repair and genome maintenance.34 Although the significance of PARP cleavage during apoptosis is not clear, it can be used as a marker of activation of CED-3/ICE–like proteases and apoptosis.35-38 

CED-3/ICE–like proteases are involved in the apoptosis of different cell lines. Recently, involvement of CED-3/ICE–like proteases in the apoptosis of Ramos-Burkitt lymphoma cells has been reported.39 However, the implication of these proteases in the apoptosis of primary tumor cells has not been studied. Here we attempt to determine whether CED-3/ICE–like proteases are involved in the apoptosis of B-CLL cells. The knowledge of the mechanisms underlying B-CLL apoptosis could contribute to the design of new treatments for B-CLL.

Patients.Eleven patients (six men and five women) with B-CLL, who had not received treatment, median age 64 years (range, 47 to 75 years) were studied. B-CLL was diagnosed according to standard clinical and laboratory criteria. The median peripheral blood leukocytosis was 104 × 109 leukocytes per liter (range, 19 to 425 × 109). Leukemic cells were phenotyped for cell surface markers by flow cytometry and were positive in all cases for CD5 and CD19. According to Binet's classification,40 at the time of inclusion four patients were at stage A, three patients were at stage B, and four patients were at stage C.

Reagents.12-O-tetradecanoylphorbol 13-acetate (TPA) and 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma Chemical Co (St Louis, MO). Dexamethasone was obtained from Merck KGaA (Darmstadt, Germany). Fludarabine was obtained from Schering AG (Berlin, Germany). Recombinant human IL-4 was obtained from Genzyme (Cambridge, MA). N-benzyloxycarbonyl-Val-Ala-Asp-fluromethyl ketone (Z-VAD.fmk) and N-benzyloxycarbonyl-Phe-Ala-fluromethyl ketone (Z-FA.fmk) were obtained from Enzyme Systems Products (Dublin, CA). Anti-PARP polyclonal antibody (Vi.5) raised against the recombinant human PARP overproduced in Sf9/baculovirus was kindly provided by Dr Gilbert de Murcia (Strasbourg, France).

Isolation of B-CLL cells.Peripheral blood lymphocytes from B-CLL patients were obtained from the Hematology Laboratory at Hospital Clinic, Barcelona, Spain. Mononuclear cells from peripheral blood samples were isolated by centrifugation on a Ficoll/Hypaque (Seromed, Berlin, Germany) gradient and cryopreserved in liquid nitrogen in the presence of 10% dimethyl sulfoxide (DMSO).

Cell culture.B-CLL lymphocytes were cultured immediately after the thawing of the cells at a concentration of 2 to 5 × 106 cells/mL in RPMI 1640 culture medium (GIBCO-BRL, Paisley, Scotland) supplemented with 10% heat inactivated fetal calf serum (FCS), 2 mmol/L glutamine and gentamicin 0.04 mg/mL at 37°C in a humidified atmosphere containing 5% carbon dioxide.41 Factors were added at the beginning of the culture.

Cell viability assay.Cell viability was determined by the MTT assay.42 B lymphocytes (5 × 105 cells/well) were incubated in 96-well plates in the absence or presence of factors in a final volume of 100 μL. After 48 hours, 10 μL of MTT (5 mg/mL in phosphate-buffered saline) was added to each well for an additional 6 hours. The blue MTT formazan precipitated was dissolved in 100 μL of isopropanol: 1 mol/L HCl (24:1). After 1 hour of incubation at 37°C, the absorbance values at 540 nm were determined on a multiwell plate reader. Cell viability is expressed in percentage with respect to cells incubated with 100 nmol/L TPA, which maintains cell viability.17 43 

Western blot analysis of PARP cleavage.Cells were lysed with Laemmli sample buffer44 and equal amounts of protein estimated by the BCA Protein Assay (Pierce, Rockford, IL) were separated by electrophoresis on 10% or 12% polyacrylamide gel and transferred to Immobilon-P (Millipore, Bedford, MA) membranes. After blocking for 1 hour with 5% dried skimmed milk in TBST (50 mmol/L Tris HCl pH 8.0, 150 mmol/L NaCl, 0.5% Tween-20), the filters were incubated with Vi.5 PARP antibody diluted 1:1,000 in 5% dried skimmed milk in TBST. Antibody binding was detected using a secondary antibody (swine antirabbit immunoglobulin, DAKO, Glostrup, Denmark) conjugated to horseradish peroxidase diluted 1:500 in 5% dried skimmed milk in TBST and an enhanced chemiluminescence (ECL) detection kit (Amersham, Buckinghamshire, UK).

Analysis of DNA fragmentation.Analysis of DNA fragmentation by agarose gel electrophoresis was performed essentially as previously described.45 Five million cells were pelleted and lysed in 10 mmol/L Tris-HCl pH 7.4, 0.2% Triton X-100, 1 mmol/L EDTA. After incubating for 20 minutes at 4°C, cell lysates were centrifuged at 14,000g for 15 minutes to separate low molecular weight DNA from intact chromatin. The supernatant was treated with 0.2 mg/mL of proteinase K in a buffer containing 150 mmol/L NaCl, 10 mmol/L Tris HCl pH 8.0, 40 mmol/L EDTA and 1% sodium dodecyl sulfate (SDS) for 6 hours at 37°C. The DNA preparations were extracted twice with buffered phenol to remove proteins. DNA was precipitated with 140 mmol/L NaCl and two volumes of ethanol at −20°C overnight. DNA precipitates were recovered by centrifugation at 14,000g for 15 minutes, washed twice in 70% ethanol, and air dried. DNA pellets were dissolved in 15 μL of double-distilled water and treated for 1 hour at 37°C with RNase (Boehringer Mannheim, Mannheim, Germany). A total of 5 μL of loading buffer was added to each tube and the DNA preparations were electrophoresed in 1% agarose gels. Gels were stained with ethidium bromide and visualized under ultraviolet (UV) light.

PARP cleavage during glucocorticoid-induced apoptosis of B-CLL cells.First, the effect of the incubation in the absence of any factor or in the presence of glucocorticoids on the viability of B-CLL lymphocytes from different patients was analyzed (Table 1). Different degrees of spontaneous and dexamethasone-induced loss of viability were observed after 48 hours of incubation. In agreement with previous reports,6 17 both spontaneous and dexamethasone-induced loss of viability were confirmed to be apoptosis by analysis of fragmented DNA (results not shown).

Table 1.

Cytotoxic Effect of Dexamethasone and Fludarabine on B-CLL Lymphocytes

Patient% Viability
No.ControlDexamethasoneFludarabine
99 ± 9 ND 54 ± 9 
102 ± 18 31 ± 2 28 ± 2 
65 ± 1.5 52 ± 1 27 ± 3 
29 ± 1 13 ± 0.2 7 ± 0.1 
55 ± 3 25 ± 2 21 ± 2 
25 ± 1 18 ± 1 15 ± 1 
83 ± 13 52 ± 12 37 ± 19 
69 ± 0.3 22 ± 0.3 26 ± 2 
65 ± 4 27 ± 0.4 32 ± 2 
10 100 ± 2.5 ND 32 ± 4 
11 68 ± 2 50 ± 0.3 25 ± 5 
Patient% Viability
No.ControlDexamethasoneFludarabine
99 ± 9 ND 54 ± 9 
102 ± 18 31 ± 2 28 ± 2 
65 ± 1.5 52 ± 1 27 ± 3 
29 ± 1 13 ± 0.2 7 ± 0.1 
55 ± 3 25 ± 2 21 ± 2 
25 ± 1 18 ± 1 15 ± 1 
83 ± 13 52 ± 12 37 ± 19 
69 ± 0.3 22 ± 0.3 26 ± 2 
65 ± 4 27 ± 0.4 32 ± 2 
10 100 ± 2.5 ND 32 ± 4 
11 68 ± 2 50 ± 0.3 25 ± 5 

B-CLL lymphocytes were incubated at 37°C for 48 hours in the absence of any factor (control) or with 10 μmol/L dexamethasone or fludarabine (5 μg/mL). Cell viability was determined by the MTT assay as described in Materials and Methods. Data are shown as the mean value ± SD.

Abbreviation: ND, not determined.

To study the involvement of CED-3/ICE–like proteases during the apoptosis of B-CLL cells, we determined whether PARP, the best-known substrate of these proteases, was cleaved when apoptosis was induced. Time-course and dose-response studies of PARP cleavage during glucocorticoid-induced apoptosis were performed with cells from one of the patients (patient no. 1). PARP cleavage was analyzed by immunoblotting using Vi.5 antibody against the enzyme, which recognizes both the native enzyme (116 kD) and the cleavage product (≈85 kD). Figure 1A shows that the 85-kD PARP proteolytic fragment appeared after 12 hours of incubation with 10 μmol/L dexamethasone and that this cleavage was more pronounced at 24 hours. At 48 hours, the native 116-kD PARP had almost disappeared and the total amount of PARP protein (116 kD plus 85 kD) had clearly decreased, indicating that the 85-kD protein was also being degraded. The finding that the proteolytic fragment of PARP was also observed in cells incubated without glucocorticoids for 48 hours is due to the spontaneous apoptosis that takes place in these cells when placed in culture medium.

Fig. 1.

PARP cleavage in B-CLL cells. (A) Time course of dexamethasone-induced PARP cleavage. B-CLL lymphocytes were incubated with or without 10 μmol/L dexamethasone for the indicated times. (B) Dose response of PARP cleavage. Cells were incubated for 48 hours with various concentrations of dexamethasone as indicated. PARP cleavage was analyzed by Western blot as described in Materials and Methods. The position of the native PARP (116 kD) and the proteolytic fragment (85 kD) is indicated.

Fig. 1.

PARP cleavage in B-CLL cells. (A) Time course of dexamethasone-induced PARP cleavage. B-CLL lymphocytes were incubated with or without 10 μmol/L dexamethasone for the indicated times. (B) Dose response of PARP cleavage. Cells were incubated for 48 hours with various concentrations of dexamethasone as indicated. PARP cleavage was analyzed by Western blot as described in Materials and Methods. The position of the native PARP (116 kD) and the proteolytic fragment (85 kD) is indicated.

Close modal

The dose-response study after 48 hours of incubation with dexamethasone (Fig 1B) showed that PARP cleavage was dose-dependent and detectable in the presence of 1 μmol/L dexamethasone. The proteolysis of PARP was complete when a high dose of dexamethasone (1 mmol/L) was used.

PARP cleavage was further studied in lymphocytes from eight additional B-CLL patients. Cells were incubated with two doses of dexamethasone, for 24 hours. DNA and protein extracts were obtained following incubation of cells for 24 hours in 1 or 10 μmol/L dexamethasone. Agarose gel electrophoresis of DNA had the characteristic ladder-like pattern of apoptosis (results not shown). Analysis of the protein extracts by Western blot showed that in all cases dexamethasone treatment increased the proteolysis of PARP, which was shown by an increase in the cleavage product and/or a decrease in the quantity of native enzyme. A correlation was found between viability and the degree of PARP cleavage (Fig 2). Thus, the cells most sensitive to dexamethasone (patients no. 2 and 8) showed a high dexamethasone-induced proteolysis of PARP, and the least sensitive cells (patients no. 3 and 7) had a very low degree of PARP cleavage. The spontaneous cleavage of PARP also depended on the patient studied, so cells from patients 4 and 6 had a very high degree of spontaneous cleavage of PARP, which correlated with a high spontaneous loss of viability.

Fig. 2.

Correlation between cell viability and PARP degradation. The values of cell viability for cells incubated without (○) or with 10 μmol/L dexamethasone (•) are shown in Table 1. PARP degradation was quantified by densitometric scanning of the immunoblots. Numbers beside the symbols indicate patient numbers.

Fig. 2.

Correlation between cell viability and PARP degradation. The values of cell viability for cells incubated without (○) or with 10 μmol/L dexamethasone (•) are shown in Table 1. PARP degradation was quantified by densitometric scanning of the immunoblots. Numbers beside the symbols indicate patient numbers.

Close modal

Effect of fludarabine on the cleavage of PARP.The effect of another drug that also induces apoptosis but has a different mechanism of action was next studied. Fludarabine, a purine analogue commonly used in B-CLL treatment,46 induces apoptosis in these cells.21 The effect of 5 μg/mL fludarabine on the viability of lymphocytes from B-CLL patients after 48 hours of incubation is shown in Table 1. All patients were sensitive to fludarabine and this compound induced apoptosis as shown by DNA fragmentation analysis (results not shown). We next analyzed whether fludarabine induced PARP cleavage. Incubation of B-CLL cells from six patients with fludarabine for 48 hours in vitro induced PARP cleavage in all cases (results not shown). The degree of proteolysis depended on the patient studied and ranged from 57% to 95% (mean value, 83.4 ± 14).

PKC activation and IL-4 inhibit PARP proteolysis.Factors such as the phorbol ester TPA, an activator of PKC, and IL-4 have been described as inhibitors of apoptosis in B-CLL lymphocytes.7,17 19 We studied whether these factors produced any effect on PARP cleavage. As seen in Fig 3A, incubation of B-CLL cells from three patients with 100 nmol/L TPA inhibited glucocorticoid-induced PARP cleavage. Incubation of cells from patient 6 (which had a high degree of spontaneous apoptosis) with 100 nmol/L TPA blocked PARP cleavage (Fig 3B). This effect was also observed when cells were incubated with 10 ng/mL IL-4. Finally, we tested if TPA blocked fludarabine-induced apoptosis. TPA inhibited both DNA degradation (results not shown) and PARP cleavage (Fig 3C).

Fig. 3.

Inhibition of PARP proteolysis by TPA and IL-4. (A) Inhibition of dexamethasone-induced PARP proteolysis by TPA. B-CLL lymphocytes from three patients were incubated with 100 nmol/L TPA in the presence or absence of 10 μmol/L dexamethasone for 48 hours. (B) Inhibition of spontaneous PARP proteolysis. Cells from patient 6 were incubated for 48 hours either in the absence of any factor (C) or with 100 nmol/L TPA, or IL-4 (10 ng/mL). (C) Inhibition of fludarabine-induced PARP cleavage. Cells from patient 5 were incubated with the indicated factors for 24 hours. The concentrations used were 100 nmol/L TPA and 5 μg/mL fludarabine. Western blot of PARP was performed with protein extracts from these cells as previously described.

Fig. 3.

Inhibition of PARP proteolysis by TPA and IL-4. (A) Inhibition of dexamethasone-induced PARP proteolysis by TPA. B-CLL lymphocytes from three patients were incubated with 100 nmol/L TPA in the presence or absence of 10 μmol/L dexamethasone for 48 hours. (B) Inhibition of spontaneous PARP proteolysis. Cells from patient 6 were incubated for 48 hours either in the absence of any factor (C) or with 100 nmol/L TPA, or IL-4 (10 ng/mL). (C) Inhibition of fludarabine-induced PARP cleavage. Cells from patient 5 were incubated with the indicated factors for 24 hours. The concentrations used were 100 nmol/L TPA and 5 μg/mL fludarabine. Western blot of PARP was performed with protein extracts from these cells as previously described.

Close modal

Inhibition of CED-3/ICE–like proteases blocks apoptosis of B-CLL cells.To confirm the involvement of CED-3/ICE–like proteases in the apoptosis of B-CLL cells, we used a specific inhibitor of these proteases, Z-VAD.fmk.47 The dose response study of Z-VAD.fmk on the inhibition of spontaneous and dexamethasone-induced apoptosis was performed with cells from patients 6 and 9, respectively. As seen in Fig 4A, 20 to 50 μmol/L Z-VAD.fmk decreased the proteolysis of PARP and 200 μmol/L completely blocked it. Incubation of B-CLL cells from four patients with 200 μmol/L Z-VAD.fmk for 48 hours in the presence or absence of dexamethasone showed that PARP proteolysis was inhibited in all cases studied (Fig 4B). Z-FA.fmk (200 μmol/L), a compound similar to Z-VAD.fmk, which lacks the aspartic acid residue that is necessary to inhibit CED-3/ICE–like proteases, did not block PARP degradation (data not shown). Furthermore, analysis by agarose gel electrophoresis showed that 200 μmol/L Z-VAD.fmk also inhibited both spontaneous and dexamethasone-induced DNA fragmentation almost completely (Fig 5).

Fig. 4.

Effect of the CED-3/ICE–like protease inhibitor Z-VAD.fmk on PARP proteolysis in B-CLL cells. (A) Dose response of the inhibitory effect of Z-VAD.fmk on PARP proteolysis. Cells from patient 6 were incubated without dexamethasone (○) and cells from patient 9 were incubated with 10 μmol/L dexamethasone (•), in the presence of various concentrations of Z-VAD.fmk for 48 hours. Western blots of PARP were performed as described in Materials and Methods and the inhibition of PARP cleavage was quantified by densitometric scanning of the immunoblots. (B) B lymphocytes from four B-CLL patients were incubated for 48 hours with 10 μmol/L dexamethasone in the presence or absence of 200 μmol/L Z-VAD.fmk. Z-VAD.fmk was added 1 hour before dexamethasone administration. Cells were lysed and analyzed by Western blot as described in Materials and Methods.

Fig. 4.

Effect of the CED-3/ICE–like protease inhibitor Z-VAD.fmk on PARP proteolysis in B-CLL cells. (A) Dose response of the inhibitory effect of Z-VAD.fmk on PARP proteolysis. Cells from patient 6 were incubated without dexamethasone (○) and cells from patient 9 were incubated with 10 μmol/L dexamethasone (•), in the presence of various concentrations of Z-VAD.fmk for 48 hours. Western blots of PARP were performed as described in Materials and Methods and the inhibition of PARP cleavage was quantified by densitometric scanning of the immunoblots. (B) B lymphocytes from four B-CLL patients were incubated for 48 hours with 10 μmol/L dexamethasone in the presence or absence of 200 μmol/L Z-VAD.fmk. Z-VAD.fmk was added 1 hour before dexamethasone administration. Cells were lysed and analyzed by Western blot as described in Materials and Methods.

Close modal
Fig. 5.

Effect of the CED-3/ICE–like protease inhibitor Z-VAD.fmk on DNA fragmentation in B-CLL cells. Cells from patients 5 and 9 were incubated for 24 hours with 10 μmol/L dexamethasone in the presence or absence of 200 μmol/L Z-VAD.fmk. Z-VAD.fmk was added 1 hour before dexamethasone administration. DNA was extracted and subjected to agarose gel electrophoresis as described in Materials and Methods. Similar results were obtained with cells from patients 7 and 8.

Fig. 5.

Effect of the CED-3/ICE–like protease inhibitor Z-VAD.fmk on DNA fragmentation in B-CLL cells. Cells from patients 5 and 9 were incubated for 24 hours with 10 μmol/L dexamethasone in the presence or absence of 200 μmol/L Z-VAD.fmk. Z-VAD.fmk was added 1 hour before dexamethasone administration. DNA was extracted and subjected to agarose gel electrophoresis as described in Materials and Methods. Similar results were obtained with cells from patients 7 and 8.

Close modal

Finally, we studied the effect of this inhibitor on the viability of B-CLL cells. Z-VAD.fmk (200 μmol/L) maintained B-CLL lymphocytes viability for 4 days, although incubation for longer periods of time decreased it (64% ± 8% after 7 days of incubation). The effect of Z-VAD.fmk on the viability of B-CLL lymphocytes incubated for 48 hours in the absence or presence of dexamethasone was studied. As shown in Fig 6, Z-VAD.fmk inhibited the cytotoxic effect of dexamethasone in all the patients studied. Although Z-VAD.fmk had no significant effects on B lymphocytes from patients 7, 8, and 9, in those patients with high spontaneous apoptosis (patients no. 5 and 6), Z-VAD.fmk reduced the spontaneous loss of viability.

Fig. 6.

Effect of Z-VAD.fmk on the viability of B-CLL cells. Cells from five patients were seeded in 96-microwell plates and incubated for 48 hours with the indicated factors. The concentrations used were 10 μmol/L dexamethasone and 200 μmol/L Z-VAD.fmk. Z-VAD.fmk was added 1 hour before dexamethasone administration. Cytotoxicity was analyzed by the MTT method as described in Materials and Methods. Data are shown as the mean value ± SD of two (patients 6, 8, and 9) or four (patients 5 and 7) independent experiments. Statistical significance of differences between treatments without or with Z-VAD.fmk was assayed by analysis of variance (ANOVA) (Fisher's Protected Least Significant Difference [PLSD]): * = P < .12, ** = P < .05, *** = P < .01.

Fig. 6.

Effect of Z-VAD.fmk on the viability of B-CLL cells. Cells from five patients were seeded in 96-microwell plates and incubated for 48 hours with the indicated factors. The concentrations used were 10 μmol/L dexamethasone and 200 μmol/L Z-VAD.fmk. Z-VAD.fmk was added 1 hour before dexamethasone administration. Cytotoxicity was analyzed by the MTT method as described in Materials and Methods. Data are shown as the mean value ± SD of two (patients 6, 8, and 9) or four (patients 5 and 7) independent experiments. Statistical significance of differences between treatments without or with Z-VAD.fmk was assayed by analysis of variance (ANOVA) (Fisher's Protected Least Significant Difference [PLSD]): * = P < .12, ** = P < .05, *** = P < .01.

Close modal

This report describes the involvement of CED-3/ICE–like proteases in the apoptosis of B-CLL cells. To our knowledge, this is the first report of a role for CED-3/ICE–like proteases in the apoptosis of primary cancer cells. The results presented herein show that activation of CED-3/ICE–like proteases in B-CLL cells is a common step in spontaneous, glucocorticoid- and fludarabine-induced apoptosis. Furthermore, apoptosis of B-CLL cells is blocked by a specific inhibitor of CED-3/ICE proteases, suggesting that these proteases are essential for the apoptosis of these cells.

At present, the mechanisms that control CED-3/ICE–like proteases are largely unknown.31,32 There seems to be a cascade of proteases similar to the one involved in the activation of the complement, but the signal that starts this apoptotic cascade is not known. Recently, it has been reported that CD95/FasR uses the adaptor protein FADD/MORT1 physically to engage FLICE/MACH, the apical component of a proteolytic cascade of CED-3/ICE–like proteases.48 49 

Our results also show that PKC activation inhibits spontaneous, glucocorticoid- and fludarabine-induced apoptosis and blocks PARP cleavage. Furthermore, PARP cleavage is blocked by IL-4. These findings suggest that both PKC and IL-4 signal transduction pathways cross-talk with the different apoptotic pathways in a common step upstream of the activation of the proteases that cleave PARP. This common step could be Bcl-2, as both PKC activation23 and IL-47 increase the levels of Bcl-2 protein. Recently, biochemical evidence that Bcl-2 functions upstream of the CED-3/ICE family proteases has been reported,50-52 as Bcl-2 prevents the processing of these proteases and the cleavage of poly(ADP-ribose) polymerase.

Although it has been used as a marker of apoptosis,35-38 the significance of PARP cleavage during this process is unknown. Mice with a disrupted PARP gene do not show altered apoptosis,53 however, a dominant negative of PARP induces apoptosis of transfected cells.54 PARP has been implicated in different processes including DNA repair, DNA replication, and transcription.34 Interestingly, in B-CLL cells PARP is the most abundant protein to bind to damaged DNA.55 It has been proposed that a central function of CED-3/ICE proteases in apoptosis is the cleavage of PARP and other nuclear repair proteins, thereby abolishing their critical homeostatic functions.56 

The CED-3/ICE–like proteases present in B-CLL cells have not been identified, but some of these proteases are expressed in B lymphocytes.57-59 The identification of these proteases in B-CLL cells and the knowledge of their mechanisms of control could be very important to design new therapies for this disease. In this respect, direct activation of these proteases to induce apoptosis may be achieved.

We are indebted to Dr G. de Murcia for the kind gift of PARP antibodies. We thank Drs G. Pons, A. López-Rivas, J.L. Vives-Corrons, N. Villamor, and C. Pastor and A. Becerra for their help and suggestions, Drs J. Esteve and J. Briones for their help in providing peripheral blood from patients, and R. Rycroft for language assistance.

Supported by “Fondo de Investigaciones Sanitarias de la Seguridad Social” (FIS 95/0873) and by the “Generalitat de Catalunya” (1995 SGR 00427), Spain. B.B. is the recipient of a research fellowship from Comissió Interdepartamental de Recerca i Innovació Technològica (CIRIT, Spain).

Address reprint requests to Joan Gil, PhD, Unitat de Bioquı́mica, Facultat de Medicina, Campus de Bellvitge, Universitat de Barcelona, Pavelló de Govern, 1a planta, 08907 L'Hospitalet, Spain.

1
Foon
KA
Rai
KR
Gale
RP
Chronic lymphocytic leukemia: New insights into biology and therapy.
Ann Intern Med
113
1990
525
2
Gale
RP
Caligaris-Cappio
F
Dighiero
G
Keating
M
Montserrat
E
Rai
K
Recent progress in chronic lymphocytic leukemia.
Leukemia
8
1994
1610
3
Krammer
PH
Behrmann
I
Daniel
P
Dhein
J
Debatin
KM
Regulation of apoptosis in the immune system.
Curr Opin Immunol
6
1994
279
4
Wyllie
AH
Kerr
JF
Currie
AR
Cell death: The significance of apoptosis.
Int Rev Cytol
68
1980
251
5
Mainou-Fowler
T
Prentice
AG
Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia.
Leuk Lymphoma
21
1996
369
6
Collins
RJ
Verschuer
LA
Harmon
BV
Prentice
RL
Pope
JH
Kerr
JFR
Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro.
Br J Haematol
71
1989
343
7
Dancescu
M
Rubio-Trujillo
M
Biron
G
Bron
D
Delespesse
G
Sarfati
M
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.
J Exp Med
176
1992
1319
8
Panayiotidis
P
Ganeshaguru
K
Jabbar
SAB
Hoffbrand
AV
Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro.
Br J Haematol
85
1993
439
9
Buschle
M
Campana
D
Carding
SR
Richard
C
Hoffbrand
AV
Brenner
MK
Interferon γ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.
J Exp Med
177
1993
213
10
Panayiotidis
P
Ganeshaguru
K
Jabbar
SAB
Hoffbrand
AV
Alpha-interferon (α-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro.
Br J Haematol
86
1994
169
11
Huang
RW
Tsuda
H
Takatsuki
K
Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells.
Int J Hematol
58
1993
83
12
Reittie
JE
Yong
KL
Panayiotidis
P
Hoffbrand
AV
Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia.
Leuk Lymphoma
22
1996
83
13
Francia di Celle
P
Mariani
S
Riera
L
Stacchini
A
Reato
G
Foa
R
Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.
Blood
87
1996
4382
14
Chaouchi
N
Wallon
C
Goujard
C
Tertian
G
Rudent
A
Caput
D
Ferrera
D
Minty
A
Vazquez
A
Delfraissy
JF
Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis.
Blood
87
1996
1022
15
Fluckiger
AC
Durand
I
Banchereau
J
Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells.
J Exp Med
179
1994
91
16
Mainou-Fowler
T
Craig
VA
Copplestone
A
Hamon
MD
Prentice
AG
Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression, and is inhibited by IL-4.
Blood
84
1994
2297
17
McConkey
DJ
Aguilar-Santelises
M
Hartzell
P
Eriksson
I
Mellstedt
H
Orrenius
S
Jondal
M
Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells.
J Immunol
146
1991
1072
18
Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA: 2Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol 309A:15, 1991
19
Robertson
LE
Chubb
S
Meyn
RE
Story
M
Ford
R
Hittelman
WN
Plunkett
W
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine.
Blood
81
1993
143
20
Begleiter A, Lee K, Israels LG, Mowat MRA, Johnston JB: Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 8:S103, 1994 (suppl 1)
21
Zinzani
PL
Buzzi
M
Farabegoli
P
Tosi
P
Fortuna
A
Visani
G
Martinelli
G
Zaccaria
A
Tura
S
Induction of “in vitro” apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
Leuk Lymphoma
13
1994
95
22
Reed
JC
Bcl-2 and the regulation of programmed cell death.
J Cell Biol
124
1994
1
23
Schena
M
Larsson
LG
Gottardi
D
Gaidano
G
Carlsson
M
Nilsson
K
Caligaris-Cappio
F
Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells.
Blood
79
1992
2981
24
Mariano
MT
Moretti
L
Donelli
A
Grantini
M
Montagnani
G
Di Prisco
AU
Torelli
G
Torelli
U
Narni
F
bcl-2 gene expression in hematopoietic cell differentiation.
Blood
80
1992
768
25
Hanada
M
Delia
D
Aiello
A
Stadtmauer
E
Reed
JC
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.
Blood
82
1993
1820
26
Cory
S
Regulation of lymphocyte survival by the bcl-2 gene family.
Annu Rev Immunol
13
1995
513
27
Yang
E
Korsmeyer
SJ
Molecular thanatopsis: A discourse on the BCL2 family and cell death.
Blood
88
1996
386
28
Hockenbery
DM
Oltvai
ZN
Yin
XM
Milliman
CL
Korsmeyer
SJ
Bcl-2 functions in an antioxidant pathway to prevent apoptosis.
Cell
75
1993
241
29
Kane
DJ
Sarafian
TA
Anton
R
Hahn
H
Butler
Gralla E
Selverstone
Valentine J
Örd
T
Bredesen
DE
Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species.
Science
262
1993
1274
30
Lam
M
Dubyak
G
Chen
L
Nunez
G
Miesfeld
RL
Distelhorst
CW
Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes.
Proc Natl Acad Sci USA
91
1994
6569
31
Martin
SJ
Green
DR
Protease activation during apoptosis: Death by a thousand cuts?
Cell
82
1995
349
32
Chinnaiyan
AM
Dixit
VM
The cell-death machine.
Curr Biol
6
1996
555
33
Henkart
PA
ICE family of proteases: Mediators of all apoptotic cell death?
Immunity
4
1996
195
34
De Murcia
G
Ménissier de Murcia
J
Poly(ADP-ribose) polymerase: A molecular nick-sensor.
Trends Biochem Sci
19
1994
172
35
Kaufmann
SH
Desnoyers
S
Ottaviano
Y
Davidson
NE
Poirier
GG
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis.
Cancer Res
53
1993
3976
36
Lazebnik
YA
Kaufmann
SH
Desnoyers
S
Poirier
GG
Earnshaw
WC
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.
Nature
371
1994
346
37
Tewari
M
Quan
LT
O'Rourke
K
Desnoyers
S
Zeng
Z
Beidler
DR
Poirier
GG
Salvesen
GS
Dixit
VM
Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.
Cell
81
1995
801
38
Nicholson
DW
Ali
A
Thornberry
NA
Vaillancourt
JP
Ding
CK
Gallant
M
Gareau
Y
Griffin
PR
Labelle
M
Lazebnik
YA
Munday
NA
Raju
SM
Smulson
ME
Yamin
TT
Yu
VL
Miller
DK
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.
Nature
376
1995
37
39
An
S
Knox
KA
Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP.
FEBS Lett
386
1996
115
40
Binet
JL
Leporria
M
Dighiero
G
Charron
P
D'Athis
P
Vaugier
G
Merle-Beral
H
Natali
JC
Raphaël
M
Nizet
B
Follezou
JY
A clinical staging system for chronic lymphocytic leukemia.
Cancer
40
1977
855
41
Carballo
E
Colomer
D
Vives
Corrons JL
Blackshear
PJ
Gil
J
Characterization and purification of a protein kinase C substrate in human B cells.
J Immunol
156
1996
1709
42
Mosmann
T
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays.
J Immunol Methods
65
1983
55
43
Forbes
IJ
Zalewski
PD
Giannakis
C
Cowled
PA
Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester.
Exp Cell Res
198
1992
367
44
Laemmli UK:Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680, 1970
45
Ascaso
R
Marvel
J
Collins
MKL
López-Rivas
A
Interleukin-3 and Bcl-2 cooperatively inhibit etoposide-induced apoptosis in a murine pre-B cell line.
Eur J Immunol
24
1994
537
46
Montserrat
E
Rozman
C
Chronic lymphocytic leukemia: Present status.
Ann Oncol
6
1995
219
47
Dolle
RE
Singh
J
Rinker
J
Hoyer
D
Prasad
CV
Graybill
TL
Salvino
JM
Helaszek
CT
Miller
RE
Ator
MA
Aspartyl alpha-((1-phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl ketones as interleukin-1 beta converting enzyme inhibitors. Significance of the P1 and P3 amido nitrogens for enzyme-peptide inhibitor binding.
J Med Chem
37
1994
3863
48
Boldin
MP
Goncharov
TM
Goltsev
YV
Wallach
D
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.
Cell
85
1996
803
49
Muzio
M
Chinnaiyan
AM
Kischkel
FC
O'Rourke
K
Shevchenko
A
Ni
J
Scaffidi
C
Bretz
JD
Zhang
M
Gentz
R
Mann
M
Krammer
PH
Peter
ME
Dixit
VM
FLICE, a novel FADD-homologous ICE/CED-3/-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex.
Cell
85
1996
817
50
Chinnaiyan
AM
Orth
K
O'Rourke
K
Duan
H
Poirier
GG
Dixit
VM
Molecular ordering of the cell death pathway.
J Biol Chem
271
1996
4573
51
Boulakia
CA
Chen
G
Ng
FWH
Teodoro
JG
Branton
PE
Nicholson
DW
Poirier
GG
Shore
GC
Bcl-2 and adenovirus E1B 19 kDa protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase.
Oncogene
12
1996
529
52
Monney
L
Otter
I
Olivier
R
Ravn
U
Mirzasaleh
H
Fellay
I
Poirier
GG
Borner
C
Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/Apopain.
Biochem Biophys Res Commun
221
1996
340
53
Wang
ZQ
Auer
B
Stingl
L
Berghammer
H
Haidacher
D
Schweiger
M
Wagner
EF
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Genes Dev
9
1995
509
54
Schreiber
V
Hunting
D
Trucco
C
Gowans
B
Grunwald
D
de Murcia
G
Menissier de Murcia
J
A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage.
Proc Natl Acad Sci USA
92
1995
4753
55
Bramson
J
Prévost
J
Malapetsa
PA
Noë
AJ
Poirier
GG
DesNoyers
S
Alaoui-Jamali
M
Panasci
L
Poly(ADP-ribose) polymerase can bind melphalan damaged DNA.
Cancer Res
53
1993
5370
56
Casciola-Rosen
L
Nicholson
DW
Chong
T
Rowan
KR
Thornberry
NA
Miller
DK
Rosen
A
Apopain/CPP32 cleaves proteins that are essential for cellular repair: A fundamental principle of apoptotic death.
J Exp Med
183
1996
1957
57
Fernandes-Alnemri
T
Takahashi
A
Armstrong
R
Krebs
J
Fritz
L
Tomaselli
KJ
Wang
L
Yu
Z
Croce
CM
Salveson
G
Earnshaw
WC
Litwack
G
Alnemri
ES
Mch3, a novel human apoptotic cysteine protease highly related to CPP32.
Cancer Res
55
1995
6045
58
Fernandes-Alnemri
T
Litwack
G
Alnemri
ES
Mch2, a new member of the apoptotic Ced-3/Ice cysteine protease gene family.
Cancer Res
55
1995
2737
59
Fernandes-Alnemri
T
Litwack
G
Alnemri
ES
CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme.
J Biol Chem
269
1994
30761
Sign in via your Institution